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To expand the armamentarium of treatment for chronic kidney disease (CKD), we explored the utility of boosting endogenously
synthesized N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), which is augmented by inhibition of the angiotensin converting
enzyme. Male BALB/c mice underwent unilateral ureteral ligation (UUO) or sham operation and received exogenously
administered Ac-SDKP delivered via a subcutaneous osmotic minipump or Captopril treatment by oral gavage. Seven days after
UUO, there were significant reductions in the expression of both collagen 1 and collagen 3 in kidneys treated with Ac-SDKP or
Captopril, and there was a trend towards reductions in collagen IV, 𝛼-SMA, and MCP-1 versus control. However, no significant
attenuation of interstitial injury or macrophage infiltration was observed. These findings are in contrary to observations in other
models and underscore the fact that a longer treatment time frame may be required to yield anti-inflammatory effects in BALB/c
mice treated with Ac-SDKP compared to untreated mice. Finding an effective treatment regimen for CKD requires fine-tuning of
pharmacologic protocols.
1. Introduction
Progression of chronic kidney disease (CKD) to end-stage
renal disease (ESRD) is characterized by pathogenic mech-
anisms that converge upon a common pathway leading
to progressive interstitial fibrosis, peritubular capillary loss,
and destruction of functioning nephrons [1]. Currently,
renin-angiotensin system (RAS) blockade with angiotensin-
converting enzyme (ACE) inhibitors or angiotensin II recep-
tor blockers (ARB) is currently the best-documented treat-
ment strategy to delay the progression of CKD. However, it
remains evident that CKD continues to progress relentlessly
to ESRD [2] despite maximal RAS inhibition coupled with
stringent blood pressure and glycemic control.The search for
a novel therapeutic agent to retard CKD has turned to N-
acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP).
Ac-SDKP is an endogenous tetrapeptide that regulates the
proliferation of pluripotent hematopoietic stem cells [3]. It
is normally present in the circulation [4] and is exclusively
degraded by ACE. There are data to suggest that, in addition
to its antiproliferative effects on the hematopoietic system,
Ac-SDKP may possess cardiac and renal anti-inflammatory
and antifibrotic properties as demonstrated in rat models of
hypertension [5, 6], acutemyocardial infarction [7], and acute
anti-GBMnephritis [8]. Furthermore, studies have elucidated
that the renoprotective action of ACE inhibitors may be
mediated viaAc-SDKP [9].However, in vivo studies to dissect
the renoprotective effects of Ac-SDKP in robust models that
recapitulate the pathological changes of human CKD are
lacking.
The evolution of CKD to ESRD is well reproduced by
unilateral ureteric obstruction (UUO) murine model. Char-
acteristically, macrophage recruitment begins by day 3. In
addition, accelerated tubulointerstitial fibrosis with increased
matrix deposition and resultant tubular atrophy occur within
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a week after ureteric ligation [10]. These lesions are highly
reproducible in various murine strains including BALB/C
mice [11]. In this study, we explored the potential renopro-
tective effects of Ac-SDKP in the UUOmurine model.
2. Materials and Methods
2.1. Mouse Model of Unilateral Ureteral Obstruction. All
animal experiments were approved by the Committee on
the Use of Live Animals in Teaching and Research of The
University of Hong Kong and were conducted in accordance
with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals.
Male BALB/C mice (Laboratory Animal Unit, The Uni-
versity of Hong Kong, HK) underwent a sham operation
or unilateral ureteral obstruction (UUO) at 12 weeks of
age, as previously described [5, 12]. Briefly, mice were sub-
jected to general anesthesia during which the left ureter
was exposed through a midabdominal incision and ligated.
Sham-operated mice had their ureters exposed and manip-
ulated without ligation. UUO mice were then subjected to
the following treatment: (i) vehicle (control), (ii) Ac-SDPK,
and (iii) Captopril. Ac-SDKP was delivered at 1mg/kg/day
via surgically implanted subcutaneous osmotic minipumps
(Alzet, Cupertino, CA, USA). Captopril was fed by oral
gavage at 30mg/kg/day. All mice were sacrificed on day 7
and the left kidney of all animals was harvested for further
analysis. Harvested kidneys were either embedded in 10%
neutral buffered formalin for histological examination or
snap-frozen in liquid nitrogen and stored at−80∘C for further
proteomic analyses. Prior to sacrifice, blood samples were
collected for the measurement of plasma Ac-SDKP level by
enzyme immunoassay kit (Bertin Pharm, France).
2.2. RNA Extraction and Real-Time PCR. Total RNAs were
isolated from the cortex of the kidney using NucleoSpin
RNA/protein kit (Macherey-Negel, Duren, Germany). The
mRNA expression was analyzed by ABI 7500 Real-Time PCR
System (Applied Biosystems, Carlsbad, CA, USA) according
to manufacturer’s instructions. Briefly, two micrograms of
total RNAs were reverse transcribed to cDNA and sub-
sequently amplified using SYBR Green Master Mix with
following primers: ICAM-1, forward-TGGCCTGGGGGA-
TGCACACT and reverse-GGCTGTAGGTGGGTCCGGG;
MCP-1, forward-CTCTTCCTCCACCACCAT and reverse-
CTCTCCAGCCTACTCATTG; TGF-𝛽, forward-AGGGCT-
ACCATGCCAACTTCT and reverse-CCGGGTTGTGTT-
GGTTGTACA; Col1, forward-TGTGTGCGATGACGT-
GCAAT and reverse-GGGTCCCTCGACTCCTACA; Col3,
forward-ACGTAGATGAATTGGGATGCAG and reverse-
GGGTTGGGCAGTCTAGTG; Col4, forward-CCGGGA-
TTTACTGGACCACC and reverse-CCCTTGCTCTCC-
CTTGTCA; 𝛼-SMA, forward-GTGCTATGTCGCTCT-
GGACTTTGA and reverse-ATGAAAGATGGCTGGAAG-
AGGGTC. Data were analyzed using SDS software (Applied
Biosystems). The mRNA expression was normalized with 𝛽-
actin and presented as relative fold change against control
mice.
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Figure 1: Plasma Ac-SDKP levels in different experimental groups.
Data were expressed as mean ± SEM. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 <
0.001 versus the corresponding group of sham-operated mice; #𝑃 <
0.05; ##𝑃 < 0.01 versus UUO-vehicle animals in the same operation
group.
2.3. Renal Histology. Paraffin-embedded renal sections
(4 𝜇m) were dewaxed using standard sequential techniques
and stained with periodic acid-Schiff reagent. Histological
changes of the renal cortex were examined under the micro-
scope through a high-power (×400) field. Tubulointerstitial
damage was graded from 0–5 (1 ≤ 10%; 2 = 10–25%; 3 =
26–50%; 4 = 51–75%; 6 ≥ 95%) as described previously
[13, 14]. Change in renal fibrosis was determined in Masson’s
Trichrome stained kidney section.
2.4. Immunohistochemistry. Immunohistochemical analyses
were performed on paraffin-embedded renal sections (4 𝜇m)
as previously described [15]. The sections were quenched
with 3% hydrogen peroxide, blocked by 2% BSA, and then
stained overnight with anti-F4/80 (AbD Serotec, Kidlington,
UK), anticollagen 1, and anticollagen 3 antibodies (South-
ern BioTech, Birmingham, AL, USA). The stained sections
were subsequently incubated with peroxidase conjugated
secondary antibodies (Dako, Carpinteria, CA, USA). The
immunocomplexes were visualized using DAB substrate
from Envision Plus system (Dako). All sections were coun-
terstained with hematoxylin before mounting. The number
of F4/80+ cells in the tubulointerstitium was counted in 10
equivalent high-power (400x) fields and was expressed as the
average number of cells per square millimeter.
2.5. Western Blot Analysis. Protein from renal cortical tissue
was extracted with RIPA lysis buffer (Millipore, Bedford,
MA, USA). Equal amount of proteins was resolved in
12% SDS-PAGE gel and transferred to PVDF membrane.
After blocking with 5% nonfat milk, the membranes were
incubated overnight with anti-𝛼-SMA (Sigma-Aldrich, St.
Louis, MO, USA) and subsequently incubated with peroxi-
dase conjugated secondary antibodies. The immunocomplex
was visualized with ECL prime chemiluminescence (GE
Healthcare, Buckinghamshire, UK) using ChemiDoc XRS+
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Figure 2: Histological changes. (a–d) PAS staining at day 7 of control animals (a), UUO operated animals (b), UUO animals with Ac-SDKP
treatment (c), and UUO animals with Captopril treatment (d). Magnification (400x). (e) Tubulointerstitial injury index of renal cortex for
assessing tubular and interstitial damage and graded in an observer-blinded manner from an arbitrary scale of 0–5 (1 ≤ 10%; 2 = 10–25%; 3 =
26–50%; 4 = 51–75%; 5 = 76–95%; 6 ≥ 95%).
system (Bio-Rad, Hercules, CA, USA). Quantification of
protein bands was performed by the ImageJ program (NIH,
Bethesda, MD, USA) and was normalized to 𝛽-actin level.
2.6. Statistical Analysis. All data were expressed as mean ±
SEM from three independent experiments. The difference
between groups was evaluated by unpaired t-test using
GraphPad Prism, version 5 (GraphPad Software, San Diego,
CA, USA). Data were considered statistically significant
at ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001 versus
the corresponding group of sham-operated mice; #𝑃 < 0.05;
##
𝑃 < 0.01 versus UUO-vehicle animals in the same opera-
tion group.
3. Results
3.1. Ac-SDKP Levels. Compared to sham-operated and vehi-
cle mice, Captopril administration significantly elevated
endogenous levels of Ac-SDKP in the plasma. Exogenous Ac-
SDKP administration was also able to achieve supraphysio-
logical plasma peptide levels (Figure 1).
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Figure 3: Macrophage infiltration. (a–d) F4/80+ve cells at day 7 of control animals (a), UUO operated animals (b), UUO animals with Ac-
SDKP treatment (c), and UUO animals with Captopril treatment (d). Magnification (400x). (e) F4/80+ve cells counted from 10 randomly
selected fields.
3.2. Morphological Findings. Kidneys from the control group
as well as the nonobstructed contralateral kidneys from the
operatedmice groups revealed no histological aberrancies on
morphological examination. Kidneys obstructed by ureteric
ligation developed severe interstitial fibrosis and tubular
atrophy whilst glomeruli were well preserved and unaffected.
The level of resultant tubulointerstitial injury compared to the
control groupwas statistically significant. However, following
Ac-SDKP or Captopril administration, no significant attenu-
ation of interstitial injury was observed (Figure 2).
3.3. Effects of Ac-SDKP on Inflammation. Macrophage infil-
tration was significantly increased in obstructed kidneys as
compared to control kidneys. However, no significant reduc-
tionwasmediated via the administration ofAc-SDKPorCap-
topril (Figure 3). Staining for lymphocytes also demonstrated
an increase in infiltration following UUO. Similarly, no
observable decrement was produced after the administration
of Ac-SDKP or Captopril (Figure 4). In concert with this,
induced ICAM-1 (an important chemotactic cytokine that
mediates cellular adhesion to allow leukocytic transmigration
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Figure 4: Lymphocytic infiltration. (a–d) CD45+ve cells at day 7 of control animals (a), UUO operated animals (b), UUO animals with
Ac-SDKP treatment (c), and UUO animals with Captopril treatment (d). Magnification (400x).
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Figure 5: Renal fibrosis by Masson’s Trichrome staining at day 7 of (a) control, (b) UUO treatment, (c) UUO with Ac-SDKP treatment, and
(d) UUO with Captopril treatment group. Magnification (400x).
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Figure 6: Collagen I expression in renal cortical tissue. (a–d) Representative immunohistochemical staining of protein expression from
control animals (a), UUO operated animals (b), UUO animals with Ac-SDKP treatment (c), and UUO animals with Captopril treatment (d).
Magnification (400x). (e) Quantitative analysis of mRNA expression by qPCR.
for regions of inflammation) was not downregulated by Ac-
SDKP or Captopril (Figure 9).
3.4. Effects of Ac-SDKP on Fibrosis. UUO injury induced
interstitial expression of collagen fibrils as demonstrated by
Masson’s Trichrome staining (Figure 5). The expressions of
collagen I and collagen III in the renal cortical tissue were
both significantly increased by UUO as compared to control.
These were both attenuated by the administration of Ac-
SDKPandCaptopril. Significant reductions inmRNAexpres-
sion by real-time PCRwere demonstrated that was supported
by decreased immunohistochemical staining of both collagen
1 and collagen 3 in kidneys treated with Ac-SDKP and
Captopril (Figures 6 and 7). A trend towards reductions in
collagen IV, 𝛼-SMA, TGF-𝛽, and MCP-1 expression was also
observed in the groups treated with Ac-SDKP and Captopril
(Figures 8 and 9).
4. Discussion
Unilateral ureteric obstruction (UUO) is a robust model
that leads to renal injury characterized by tubular cell
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Figure 7: Collagen III expression in renal cortical tissue. (a–d) Representative immunohistochemical staining of protein expression from
control animals (a), UUO operated animals (b), UUO animals with Ac-SDKP treatment (c), and UUO animals with Captopril treatment (d).
Magnification (400x). (e) Quantitative analysis of mRNA expression by qPCR.
injury, interstitial inflammation, and fibrosis [16]. Mecha-
nistically, local expression of chemokines following UUO
attracts blood-derived macrophages into the renal corti-
cal interstitium. In turn, the cytokines and growth fac-
tors secreted by the inflammatory infiltrate result in the
accumulation activated 𝛼-SMA positive fibroblasts in the
tubulointerstitial space by a process of recruitment and
tubular epithelial-mesenchymal transition (EMT) [10]. The
UUOmodel was therefore a goodmodel for the investigation
of the anti-inflammatory and antifibrotic properties of Ac-
SDKP. Indeed, when compared to the sham-operated mice,
UUOmice developed significantmacrophage infiltration and
tubulointerstitial fibrosis in the kidney cortex at day 7 after
ligation [17].
Previous in vivo studies demonstrated Ac-SDKP to sig-
nificantly attenuate interstitial inflammation and tubuloin-
terstitial fibrosis in deoxycorticosterone acetate-salt hyper-
tensive mice [18] and aldosterone-salt-treated rats [5] and
rats induced with acute anti-GBM nephritis [8]. A recent
study also found beneficial effects of Ac-SDKP in dampening
renal inflammation and fibrosis induced by UUO in Wistar
rats [19]. However, in our current study using BALB/C
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Figure 8: Alpha smooth muscle actin expression in renal cortical tissue. (a) Quantitative analysis of mRNA expression by qPCR. (b)
Quantitative analysis of protein expression of different groups, with representative Western blot gels shown in duplicate at the top.
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Figure 9: Quantitative analysis of renal cortical mRNA expression of different proinflammatory/profibrotic cytokine genes by real-time PCR
in the various experimental groups.
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mice, the level of resultant tubulointerstitial injury was not
significantly different between the vehicle group and the
groups treated with Ac-SDKP and Captopril. The validity of
our observations is strengthened by the fact that significant
peptide levels of Ac-SDKP were achieved via exogenous
administration in the Ac-SDKP group and ACE inhibition in
the Captopril group.
One reason that may account for this discrepancy may be
the difference in the period of treatment. A shorter treatment
duration of 7 days in our study, compared with 14 days
in the other study, may not have allowed enough time for
the difference in effect to be established. In support of this,
UUO induced collagen 1 and collagen 3 gene expression in
the cortical tissue were significantly suppressed by Ac-SDKP
to suggest an antifibrotic advantage. A similar trend, albeit
statistically insignificant, was found in 𝛼-SMA expression.
We therefore postulate that a longer treatment time frame
is required to observe a morphological difference in the
histology of BALB/C mice treated with Ac-SDKP compared
to untreated mice. The expressions of these fibrotic markers
were also ameliorated by Captopril, which seems to suggest
the actions of Ac-SDKP to parallel that of Captopril or that
ACE inhibitors may in part act via raising endogenous levels
of Ac-SDKP.
Renal interstitial inflammation which plays a pivotal role
in the induction and propagation of interstitial fibrosis is
characterized bymacrophage and lymphocytic infiltration. In
contrast to previous studies, we were unable to demonstrate
any anti-inflammatory effects with the administration of
Ac-SDKP. Being consistent, this lack of benefit was equally
observed in the Captopril group. It is uncertain as to whether
this results from a difference in the animal model utilized or
that insufficient duration of treatment was employed.
In summary, the UUO model in our study allowed us to
demonstrate that Ac-SDKP can attenuate the gene expression
of fibrotic markers. The lack of morphological difference
detected may be due to insufficient treatment time. Thus,
Ac-SDKP may serve as a potential therapeutic agent for the
treatment of CKD.
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